New hope for rare cancer: drug combo targets Tough-to-Treat neuroendocrine tumors
NCT ID NCT05746208
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two drugs, lenvatinib and pembrolizumab, in people with a rare and aggressive type of neuroendocrine tumor called well-differentiated grade 3 (WD G3). The goal is to see if the treatment can shrink tumors or stop them from growing. About 29 adults with advanced tumors that cannot be removed by surgery will take part. The study also uses special scans and blood tests to learn more about how the tumors respond.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE NEUROENDOCRINE CARCINOMA, ANY SITE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Three-Drug cocktail shrink Hard-to-Treat neuroendocrine tumors?
- Experimental drug targets Hard-to-Treat neuroendocrine cancers
- New camera could make cancer treatment safer by better tracking radiation
- Radioactive drug targets hard-to-treat neuroendocrine tumors in early trial
- New imaging agent could sharpen detection of rare tumors
- Which catheter delivers better chemo to liver tumors? small trial aims to find out